LSV Asset Management Has $62.01 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY

LSV Asset Management raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,657,093 shares of the company’s stock after buying an additional 62,200 shares during the period. LSV Asset Management’s holdings in Harmony Biosciences were worth $62,008,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in shares of Harmony Biosciences by 6.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,691,581 shares of the company’s stock worth $46,620,000 after buying an additional 109,405 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Harmony Biosciences by 11.2% during the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after buying an additional 168,145 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Harmony Biosciences by 42.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock worth $35,701,000 after buying an additional 388,472 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Harmony Biosciences by 4,102.4% during the fourth quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after buying an additional 938,783 shares in the last quarter. Finally, Boston Partners increased its holdings in shares of Harmony Biosciences by 24.5% during the third quarter. Boston Partners now owns 753,952 shares of the company’s stock worth $20,697,000 after buying an additional 148,457 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $30.15 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The firm has a market cap of $1.75 billion, a P/E ratio of 12.16, a P/E/G ratio of 0.20 and a beta of 0.97. The firm has a 50 day simple moving average of $29.43 and a 200 day simple moving average of $33.16. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.78 EPS. Sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Needham & Company LLC dropped their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Bank of America dropped their price objective on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a report on Wednesday, February 25th. Weiss Ratings lowered shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Truist Financial raised their price target on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a report on Friday, May 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a report on Friday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $40.89.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.